Dragomir Krastev

9PUBLICATIONS
99CO-AUTHORS
Molecular targetsHaematological tumoursMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 02, 2026
Nucleophagy removes cytotoxic trapped PARP1.

|Mar 12, 2026
Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors.

Callum Walker, Gabriel Kollarovic, Daniel Weekes

|Jul 29, 2025
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.

Roman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki

|Jul 08, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

Joan Kyula-Currie, Victoria Roulstone, James Wright

|Feb 12, 2025
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.

James Stewart, Dragomir B Krastev, Rachel Brough

|Jul 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.

Stephen J Pettitt, Nan Shao, Diana Zatreanu

Pageof 2

Frequent Collaborators

9 joint publications

Christopher J Lord

7 joint publications

Stephen Pettitt

6 joint publications

Jyoti S Choudhary

5 joint publications

Andrew Nj Tutt